Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orca-T in Advanced Hematologic Malignancies Undergoing HLA-Mismatched AlloHCT
NCT06551584Phase 1Recruiting
- Sponsor
- Stanford University
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of regulatory T-cell enriched infusion in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), mixed phenotype acute leukemia (MPAL) and 1 more, sponsored by Stanford University. Primary endpoint: Proportion of Patients Without Severe Transplant-Related Adverse Events at Day 100. Started Dec 2025; status: recruiting.
02
Drugs
regulatory T-cell enriched infusion
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)mixed phenotype acute leukemia (MPAL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06551584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06551584.